BR112017018230A2 - forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina - Google Patents

forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina

Info

Publication number
BR112017018230A2
BR112017018230A2 BR112017018230A BR112017018230A BR112017018230A2 BR 112017018230 A2 BR112017018230 A2 BR 112017018230A2 BR 112017018230 A BR112017018230 A BR 112017018230A BR 112017018230 A BR112017018230 A BR 112017018230A BR 112017018230 A2 BR112017018230 A2 BR 112017018230A2
Authority
BR
Brazil
Prior art keywords
crystalline form
disorder
disease
treating
composition
Prior art date
Application number
BR112017018230A
Other languages
English (en)
Portuguese (pt)
Inventor
M Lindemann Christopher
Stults Jeffrey
LUBACH Joseph
l spencer Keith
Liu Weidong
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017018230(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of BR112017018230A2 publication Critical patent/BR112017018230A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112017018230A 2015-02-26 2016-02-26 forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina BR112017018230A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
BR112017018230A2 true BR112017018230A2 (pt) 2018-04-17

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018230A BR112017018230A2 (pt) 2015-02-26 2016-02-26 forma cristalina, composição, formulação farmacêutica, método para tratar uma doença ou distúrbio e utilização de uma forma cristalina

Country Status (21)

Country Link
US (2) US20160251350A1 (cg-RX-API-DMAC7.html)
EP (1) EP3262042A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018506562A (cg-RX-API-DMAC7.html)
KR (1) KR20170118762A (cg-RX-API-DMAC7.html)
CN (1) CN107406447A (cg-RX-API-DMAC7.html)
AR (1) AR103801A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016225070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017018230A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976665A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017009662A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170439A (cg-RX-API-DMAC7.html)
HK (1) HK1246786A1 (cg-RX-API-DMAC7.html)
IL (1) IL254115A0 (cg-RX-API-DMAC7.html)
MA (1) MA41599A (cg-RX-API-DMAC7.html)
MX (1) MX2017010888A (cg-RX-API-DMAC7.html)
PE (1) PE20171327A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501532A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017133093A (cg-RX-API-DMAC7.html)
SG (1) SG11201706824TA (cg-RX-API-DMAC7.html)
WO (1) WO2016138458A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
HK1246786A1 (zh) 2018-09-14
CN107406447A (zh) 2017-11-28
CL2017002180A1 (es) 2018-03-16
IL254115A0 (en) 2017-10-31
KR20170118762A (ko) 2017-10-25
CR20170439A (es) 2018-01-08
PE20171327A1 (es) 2017-09-12
RU2017133093A (ru) 2019-03-26
EP3262042A1 (en) 2018-01-03
WO2016138458A1 (en) 2016-09-01
AU2016225070A1 (en) 2017-09-07
US20180282324A1 (en) 2018-10-04
US20160251350A1 (en) 2016-09-01
RU2017133093A3 (cg-RX-API-DMAC7.html) 2019-08-23
PH12017501532A1 (en) 2018-02-05
CA2976665A1 (en) 2016-09-01
AR103801A1 (es) 2017-06-07
MA41599A (fr) 2018-01-02
JP2018506562A (ja) 2018-03-08
CO2017009662A2 (es) 2018-02-28
MX2017010888A (es) 2017-12-15
SG11201706824TA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
PL3601268T3 (pl) Proces przygotowania 6-(cyklopropanoamido)-4-((2-metoksy-3-(1-metylo-1h-1,2,4-triazol-3-ylo)fenylo)amino)-n-(metylo-d3)pirydyno-3-karboksyamidu
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
PH12018501362A1 (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
BR112017026132A2 (pt) piridinas substituídas e métodos de uso
BR112016021130A2 (pt) Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
NI201800112A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6- (trifluorometil)piridin-2-carboxamida
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX393177B (es) Formulacion granulada de 5-metil-1-fenil-2-(1h)-piridona y metodo para elaborarla.
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
NZ735631A (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
MX2021015656A (es) Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido).
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
DK3634968T3 (da) Heterocykliske forbindelser, der kan anvendes som antibakterielle midler, og fremgangsmåde til fremstilling heraf
CY1125399T1 (el) Διαρυλικες συνθεσεις και μεθοδοι για τη διαμορφωση ενος καταρρακτη κινασης
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
IL262494A (en) A pharmaceutical combination preparation containing Ivacaptor and Lomaceptor complex compositions, their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
CO2017009662A2 (es) Formas cristalinas de un compuesto de pirrolopiridina
DK3398946T3 (da) Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme
MX2020009412A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements